Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:32 pm Purchase |
2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
Paradigm BioCapital Advisors LP | 4,086,346 9.200% |
1,888,034 (+85.89%) |
Filing History |
| 2024-11-12 6:00 pm Unchanged |
2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
The Vanguard Group | 2,035,363 4.560% |
0 (Unchanged) |
Filing History |
| 2024-11-04 2:16 pm Sale |
2024-09-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
The Vanguard Group | 2,035,363 4.560% |
-208,875 (-9.31%) |
Filing History |
| 2024-04-08 5:09 pm Purchase |
2024-03-27 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
Paradigm BioCapital Advisors LP | 2,198,312 5.020% |
2,198,312 (New Position) |
Filing History |
| 2024-02-14 4:08 pm Purchase |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
WG Biotech ApS | 4,700,533 10.700% |
395,402 (+9.18%) |
Filing History |
| 2024-02-13 5:17 pm Sale |
2023-12-29 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
The Vanguard Group | 2,244,238 5.140% |
-14,016 (-0.62%) |
Filing History |
| 2024-02-13 4:08 pm Sale |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,297,800 7.600% |
-516,053 (-13.53%) |
Filing History |
| 2024-02-06 3:59 pm Purchase |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
ACORN BIOVENTURES, L.P. | 2,761,825 6.300% |
2,761,825 (New Position) |
Filing History |
| 2024-01-26 5:26 pm Purchase |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
BLACKROCK INC BLK |
2,917,080 6.700% |
338,304 (+13.12%) |
Filing History |
| 2023-04-03 1:46 pm Purchase |
2023-03-15 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
ACORN BIOVENTURES, L.P. | 2,326,528 5.300% |
2,326,528 (New Position) |
Filing History |
| 2023-02-14 4:03 pm Purchase |
2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,813,853 8.700% |
722,899 (+23.39%) |
Filing History |
| 2023-02-14 1:50 pm Purchase |
2019-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
WG Biotech ApS | 4,305,131 9.800% |
4,305,131 (New Position) |
Filing History |
| 2023-02-09 11:37 am Purchase |
2022-12-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
The Vanguard Group | 2,258,254 5.170% |
2,258,254 (New Position) |
Filing History |
| 2023-02-01 4:54 pm Sale |
2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
BLACKROCK INC BLK |
2,578,776 5.900% |
-188,584 (-6.81%) |
Filing History |
| 2022-04-11 08:51 am Sale |
2022-03-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
WELLINGTON MANAGEMENT CO LLP | 1,910,578 4.370% |
-2,360,804 (-55.27%) |
Filing History |
| 2022-02-14 6:45 pm Purchase |
2021-11-04 | 13D | Y-mAbs Therapeutics, Inc. YMAB |
Sofinnova Venture Partners X L.P. | 2,271,611 5.200% |
160,222 (+7.59%) |
Filing History |
| 2022-02-07 5:13 pm Purchase |
2021-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,090,954 7.100% |
960,581 (+45.09%) |
Filing History |
| 2022-02-04 09:30 am Sale |
2021-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
WELLINGTON MANAGEMENT CO LLP | 4,271,382 9.790% |
-177,228 (-3.98%) |
Filing History |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
BLACKROCK INC BLK |
2,767,360 6.300% |
348,780 (+14.42%) |
Filing History |
| 2021-07-12 09:24 am Purchase |
2021-06-30 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
WELLINGTON MANAGEMENT CO LLP | 4,448,610 10.210% |
2,008,801 (+82.33%) |
Filing History |